REST THERAPEUTICS
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Private
- Established
- 2020-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
Phase 1
Withdrawn
- Conditions
- Alzheimer DiseaseTreatment Resistant DepressionPTSDMajor Depressive DisorderNeuro-Degenerative DiseaseBrain Diseases
- Interventions
- Drug: Fluoroethylnormemantine (FENM)
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- ReST Therapeutics
- Registration Number
- NCT05921929
- Locations
- 🇧🇪
CHU of Liège - Clinical Pharmacology Unit, Liège, Belgium
News
No news found